Previous 10 | Next 10 |
WATERTOWN, Mass., June 20, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, toda...
2023-06-04 07:30:00 ET Summary Hangzhou Betta Pharma acquired greater China rights for a novel non-small cell lung cancer drug from Boston’s C4 Therapeutics in a deal worth up to $392 million. Shanghai’s Impact Therapeutics out-licensed global rights (ex-China) for t...
C4 Therapeutics, Inc. (NASDAQ: CCCC) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 6.98% on the day to $3.29. C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidat...
2023-05-30 10:27:32 ET C4 Therapeutics ( NASDAQ: CCCC ) and Betta Pharmaceuticals have inked an exclusive licensing agreement for the development and commercialization of lung cancer therapy CFT8919 in Greater China, the companies announced Tuesday. Per the terms, C4 Therapeut...
2023-05-04 12:32:12 ET C4 Therapeutics press release ( NASDAQ: CCCC ): Q1 GAAP EPS of -$0.71 beats by $0.06 . Revenue of $3.76M (-50.8% Y/Y) misses by $1.7M . Cash, Cash Equivalents and Marketable Securities of $305.0 million as of March 31, 2023; Expected to P...
Preclinical Data Presented at AACR Demonstrated CFT1946 is a Potent and Mutant-Selective BRAF V600 BiDAC ™ Degrader; Phase 1/2 Clinical Trial Enrolling Patients Phase 1 Dose Escalation Data from the Ongoing Phase 1/2 Clinical Trials of CFT7455, an IKZF1/3 MonoDAC™ De...
WATERTOWN, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, tod...
2023-04-14 17:30:31 ET Gainers: Elevation Oncology ( ELEV ) +23% . Kezar Life Sciences ( KZR ) +16% . Vimeo ( VMEO ) +5% . Karyopharm Therapeutics ( KPTI ) +4% . LivaNova ( LIVN ) +3% . Losers: Silence Therapeutics&...
2023-04-12 17:16:26 ET Gainers: Dragonfly Energy Holdings ( DFLI ) +5% . C4 Therapeutics ( CCCC ) +5% . Sana Biotechnology ( SANA ) +4% . SunPower Corporation ( SPWR ) +3% . Cogent Biosciences ( COGT ) +3% . Losers: ...
C4 Therapeutics press release ( NASDAQ: CCCC ): FY GAAP EPS of -$2.62 misses by $0.13 . Revenue of $31.1M (-32.1% Y/Y) misses by $8.69M . For further details see: C4 Therapeutics GAAP EPS of -$2.62 misses by $0.13, revenue of $31.1M misses by $8.69M
News, Short Squeeze, Breakout and More Instantly...
WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that preliminary data from the monotherapy dose escalation portion of the ongoing...
WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the UBS Targeted Prote...
Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation Committee Transition Further Highlights Commitment to Strategically Transform t...